Figure 8 | Scientific Reports

Figure 8

From: Cancer-associated fibroblast-related prognostic signature predicts prognosis and immunotherapy response in pancreatic adenocarcinoma based on single-cell and bulk RNA-sequencing

Figure 8

IC50s of oxaliplatin and erlotinib in PAAD patients with low and high-risk scores and correlations between these IC50s and risk score. (A,B) IC50s of oxaliplatin and correlation between IC50s and risk scores in the TCGA cohort. (C,D) IC50s of erlotinib and correlation between IC50s and risk scores in the TCGA cohort. (E,F) IC50s of oxaliplatin and correlation between IC50s and risk scores in the ICGC cohort. (G,H) IC50s of erlotinib and correlation between IC50s and risk score in the ICGC cohort. (I) Expression of PD-L1 in the low- and high-risk groups in the TCGA cohort. (J) Correlation between expression of PD-L1 and risk scores in the TCGA cohort. (K) The risk scores in groups with different anti-PD-L1 treatment response status in the IMvigor210 cohort. NR: progressive disease (PD)/stable disease (SD), R: complete response (CR)/partial response (PR). (L) The objective response rate in the low-risk and high-risk group.

Back to article page